Blood cancer research at MPCCC links two of Australia’s largest and most experienced malignant haematology service providers with internationally respected discovery programs and leading clinical trials facilities, to integrate the best evidence–based treatments into routine patient care.
Alfred Health’s Malignant Haematology and Stem Cell Transplantation Unit provides high-acuity malignant haematology services for a catchment of approximately two million Victorians. The service has internationally recognised expertise in the treatment of multiple myeloma (A/Prof Andrew Spencer) and acute myeloid leukaemia (Dr Andrew Wei).
Alfred Health’s Malignant Haematology and Stem Cell Transplantation Unit is affiliated with the laboratory and clinical research conducted by the Australian Centre for Blood Diseases (ACBD), which is part of Monash University’s Central Clinical School.
ACBD provides the largest phase 1 & 2 clinical trials program for haematology malignancies in Australia, with major pre-clinical and clinical research platforms. Examples of current research activity include:
Major clinical trials platform for new therapies targeting BCL2 in elderly patients with AML who are not fit for intensive chemotherapy; currently recruiting for clinical trial investigating BCL-2 inhibitor ABT-199, in combination with low-dose cytarabine or decitabine. A trial investigating a new BCL2 inhibitor S 55746 has also been initiated at the Alfred Hospital under Dr Wei.
Phase 1 clinical trial to support development of antibody therapeutic KB004 , which is targeted and potentially less invasive treatment of leukaemia. Based on results of this trial, KB400 has potential to be tested on solid tumours.
Pre-clinical study which identified INPP4B overexpression is associated with chemo-resistance, early relapse, and poor overall survival, independent of other risk factors
Monash Health Haematology is a dynamic team providing care to a population of approximately 1.3 million Victorians, and includes Australia’s second largest paediatric leukaemia service. The facility is underpinned by academic research programs conducted in conjunction with the Monash Health Translation Precinct, and the Centre for Cancer Research (CCR) at the Hudson Institute of Medical Research.
Key leadership areas in clinical care and research include: Lymphoid cancer, chronic myeloid disorders, thromboembolic disease, haemoglobinopathy and transfusion medicine.
Monash Health Haematology is a lead international site for expertise and clinical trial activity in lymphoid cancer and chronic myeloid disorders. Monash has one of the largest public chronic myeloid leukaemia clinics (CML) in Australia, and has been a lead recruiter to international Phase III CML and myelodysplasia studies.
In March 2017, Monash Health in affiliation with Monash University was been approved as a “Myelodysplasia (MDS) Centre of Excellence” by the International MDS Foundation.
Leading haematology research active clinicians include: